Capstone, Spring 2026

A Methane AMC Case Study

A Methane AMC Case Study

Analytical frameworks

MCS program frameworks applied to the methane vaccine advance market commitment

01 / Core

Techno-economic analysis: what the model finds

The MCS Playbook asks three questions of every climate intervention: what is the technical potential, what does abatement cost, and where does uncertainty live? For this AMC, the answers are unusually strong across all three.

14.4:1
Benefit-cost ratio
Central scenario · 50% adoption
$11.5B
Net present value
Social benefit · 10-year horizon
$3.21
Cost per tCO₂e avoided
Baseline scenario · GWP-100

At $3.21 per tonne avoided, this AMC delivers abatement at roughly one-tenth the price of voluntary carbon market credits, which typically trade between $10 and $40 per tonne. The economic case is not marginal.

Key modeling assumptions
AssumptionValue
Efficacy (methane reduction)20% conservative baseline (TPP target: 50%)
Adoption rate25% conservative · 50% central scenario
Target population90M U.S. cattle
Program horizon10 years
AMC tail price$16.40 per dose
Social cost of methane$1,500 per tonne CH₄ (GWP-100)
Discount rate7% (OMB guidance)
BCR and NPV shift significantly with adoption and dosing assumptions. Test them in the Sensitivity Studio →

02 / LCA

Lifecycle assessment

A simplified LCA evaluates whether the lifecycle emissions of vaccine production and deployment are justified by the methane abatement achieved. The short answer is: decisively yes, by roughly two orders of magnitude.

System boundary

The LCA boundary encompasses five stages: R&D inputs (lab energy, materials, clinical trials), manufacturing (bioreactor energy, raw materials, cold chain), distribution (transport to farms, refrigeration), administration (veterinary labor, animal handling), and the use phase (methane reduction over the animal's productive lifespan). End-of-life considerations are minimal since the vaccine is metabolized by the animal.

R&D inputs
Manufacturing
Distribution
Administration
Use phase
Methane reduction

Net lifecycle impact: overwhelmingly positive

Key finding

Each vaccinated animal avoids approximately 0.014 tCH₄ per year (0.392 tCO₂e at GWP-100). Vaccine manufacturing and distribution emissions are estimated at low single-digit kg CO₂e per dose. The ratio of avoided to embodied emissions is on the order of 100:1 or greater. This intervention is not a marginal improvement on the emissions ledger.

Methodology & literature

Methodological approach ISO 14040/14044 (UC Berkeley MCS, Prof. Matthew Potts). Functional unit: one completed vaccination course per animal per year. System boundary: cradle-to-use-phase. Impact category: GWP-100. Primary sources: FAO GLEAM, EPA GHG Inventory (2024), Jensen et al. (2014) veterinary cost dataset.

FAO (2013) Tackling Climate Change Through Livestock: A Global Assessment of Emissions and Mitigation Opportunities. Global lifecycle assessment using the GLEAM model.
Beauchemin et al. (2022) Current State of Enteric Methane and the Carbon Footprint of Beef and Dairy Cattle in the United States. Animal Frontiers, 11(4), 57-68. Integrates LCA with enteric methane measurement methods.
Stanley et al. (2018) Impacts of Soil Carbon Sequestration on Life Cycle Greenhouse Gas Emissions in Midwestern USA Beef Finishing Systems. Agricultural Systems 162, 249-258. Comparative LCA of beef systems, affiliated with UC Berkeley ESPM.
Gollnow et al. (2024) Towards an Application of the Life Cycle Assessment Framework for GHG Emissions of the Dairy System: A Literature Review. Land 14(6), 1207. Critical review of LCA scope design limitations.
EPA (2024) Inventory of U.S. Greenhouse Gas Emissions and Sinks, Chapter 5: Agriculture. U.S. baseline enteric methane data.

03 / Pathways

Pathways and barriers

Sociotechnical transitions theory asks why promising technologies fail to scale even when the economics are sound. For a methane vaccine, the answer is structural: no incumbent regime punishes inaction, so no private actor has sufficient incentive to move first. The AMC is designed specifically to solve this coordination failure.

Transitions framework context

In transition theory terms, enteric methane reduction is a niche technology attempting to disrupt an established regime (conventional livestock production with no methane pricing). The regime is stable because producers face no financial penalty for methane emissions and no financial reward for reducing them. The AMC functions as a niche-stimulation mechanism: it creates an artificial demand signal that allows the niche to develop without requiring the regime itself to change first.

This framing is drawn from the Multi-Level Perspective (Geels, 2002) and the Strategic Niche Management literature (Kemp et al., 1998), as applied in the UC Berkeley MCS curriculum analytical framework.

Structural barriers

Demand uncertainty

No buyer will commit to a product that does not exist. No innovator will build a product no one is buying. The AMC breaks this deadlock by inserting legally binding demand before the product is commercial.

Addressed by AMC

Grazing system exclusion

Most existing methane mitigation options (feed additives, 3-NOP) require controlled feeding environments like feedlots or confined dairies. The majority of global cattle are pastured, leaving them without a viable solution. A vaccine is one of the few interventions that works across all production systems.

Partially addressed

Adoption friction

Even with a proven vaccine, producer uptake depends on cost, convenience, and trust. The AMC addresses this by subsidizing or fully covering the cost of vaccination and potentially bundling delivery with existing mandatory vaccines to reduce logistical burden.

Partially addressed

Verification complexity

Measuring methane reduction at the herd level is technically challenging. The AMC proposal addresses this through vaccination verification (ear tags, digital IDs, vial serial numbers) rather than direct emissions measurement, simplifying the monitoring burden.

Addressed by AMC

Political and incumbent resistance

Livestock industry stakeholders may resist framing their sector as a climate problem. The AMC sidesteps this by positioning the intervention as an investment opportunity with co-benefits (food system resilience, trade competitiveness) rather than a regulatory mandate.

Open challenge

Of the five barriers, two are structurally resolved by the AMC mechanism, two are partially mitigated through program design, and one remains open. The open challenge is the binding constraint on coalition formation.


04 / Co-benefits Forthcoming in final deliverable, May 2026

Co-benefits analysis

In the current political environment, non-climate co-benefits are often the critical path to adoption. An intervention that can be framed as a rural development investment, a trade competitiveness tool, or a food security measure commands a broader coalition than one framed solely as climate mitigation. Five dimensions are under active analysis for the final deliverable.

Dimensions under analysis

Five dimensions

Rural economic development Food system resilience Trade competitiveness Innovation spillovers Global health equity

Quantitative estimates and supporting literature forthcoming in the final deliverable.


05 / AMC Design

AMC design: governance architecture

The most consequential design choice in an AMC is not the commitment size or the tail price. It is when in the product development cycle the capital commitment is made, and what obligations it creates before a product exists. Two architectures are viable for a methane vaccine AMC.

Traditional AMC

Demand-first structure

Sponsors commit to purchasing a defined quantity at a guaranteed price once a qualifying product is commercialized. The commitment is legally binding but capital is not deployed until delivery. This maximizes signal credibility — innovators know the market exists — but does not bridge the early-stage capital gap before Phase III trials are complete.

  • High buyer signal before commercialization
  • Lower governance and coordination overhead
  • Capital deployment deferred until product approval
  • Best suited when R&D funding is separately available
Preferred when buyer coalitions can form early

Hybrid AMC + Investment

Earlier capital structure

An AMC tail guarantee is paired with upfront investment tranches — milestone-based grants or catalytic debt — that de-risk the development pathway before product approval. Capital is partially deployed during R&D, reducing the innovator's downside exposure at the cost of greater governance complexity and oversight requirements.

  • Moderate demand certainty with earlier capital activation
  • Bridges the gap when external R&D funding is insufficient
  • Can accelerate commercialization timeline if well-structured
  • Requires robust independent governance and oversight
Preferred when early capital is needed to de-risk R&D
Key design parameters

Four parameters set the economic terms of the commitment regardless of which architecture is chosen.

Tail price

The subsidized per-dose price paid above market rate — the demand premium that makes development economically viable. At $16.40/dose (baseline), this AMC targets a BCR above 14:1. Setting the tail price too low fails to attract innovators; too high reduces fund efficiency once the market is established.

Commitment size

Total fund capitalization — $534M at baseline — sets the ceiling for doses purchased at the tail price. The commitment must be large enough to justify the innovator's R&D investment while remaining within bounds that sponsors can credibly raise and deploy.

Eligibility criteria

The technical specifications a vaccine must meet to qualify: minimum efficacy threshold (≥20% methane reduction), safety requirements, dosing frequency, and delivery format. These criteria protect against underpowered products while remaining within reach of current science.

Verification protocol

How compliance is confirmed at the farm level. This AMC proposes vaccination verification — digital IDs, vial serial numbers, ear tags — rather than direct emissions measurement, substantially lowering MRV burden and making the mechanism viable in low-infrastructure settings globally.

Test how tail price and commitment size shift BCR in the Sensitivity Studio →

What's next

The next question

This analysis stress-tests one mechanism in depth. The next question is which mechanism fits which market, time horizon, and risk appetite. Phase 2 of this work addresses that directly.

The Spark Enteric Methane Navigator maps 15+ market mechanism types across funder profiles, market stages, and political contexts. It helps decision-makers identify where an AMC, carbon credit, subsidy, results-based finance, or regulatory instrument is most likely to succeed, and why. Explore the Navigator →

Next, beyond Phase 1

The Spark Enteric Methane Navigator

Phase 2 zooms out. A funder-facing decision-support tool covering 15 market mechanism types, from carbon credits to AMCs to regulatory pricing.

Continue to the Navigator →